We developed novel methods for analyzing the concentrationresponse curve of an agonist to estimate the product of observed affinity and intrinsic efficacy, expressed relative to that of a standard agonist. This parameter, termed intrinsic relative activity (RA i ), is most applicable for the analysis of responses at G protein-coupled receptors. RA i is equivalent to the potency ratios that agonists would exhibit in a hypothetical, highly sensitive assay in which all agonists behave as full agonists, even those with little intrinsic efficacy. We investigated muscarinic responses at the M 2 receptor, including stimulation of phosphoinositide hydrolysis through G Drug discovery often involves testing compounds in isolated tissues and high throughput assays to determine activity at target receptors. In the case of agonists, the measured parameters are usually EC 50 and E max , whereas the parameters of greater relevance to drug design are observed affinity and intrinsic efficacy.
ovary (CHO) cells, and stimulation of cAMP accumulation through G s in CHO cells treated with pertussis toxin. The RA i values of carbachol, oxotremorine-M, and the enantiomers of aceclidine were approximately the same in the three assay systems. In contrast, the activity of 4-[[N- [3-chlorophenyl] carbamoy]oxy-2-butynyl]trimethylammonium chloride (McN-A-343) was ϳ10-fold greater at M 2 receptors coupled to G ␣15 in HEK 293T cells compared with M 2 receptors coupled to G i in the same cells or in CHO cells. Our results show that the RA i estimate is a useful measure for quantifying agonist activity across different assay systems and for detecting agonist directed signaling.
Drug discovery often involves testing compounds in isolated tissues and high throughput assays to determine activity at target receptors. In the case of agonists, the measured parameters are usually EC 50 and E max , whereas the parameters of greater relevance to drug design are observed affinity and intrinsic efficacy.
1 If the receptor is a ligand-gated ion channel, then receptor activation can be measured directly as whole cell current, and the EC 50 and E max are reasonable estimates of observed affinity and intrinsic efficacy provided that desensitization is not excessive. It would seem that, in most instances, the observed affinity and intrinsic efficacy of an agonist for a ligand-gated ion channel would be constant, regardless of the tissue or cell in which the receptor is expressed.
The situation is more complex for a G protein-coupled receptor (GPCR). First, GPCRs are inactive in isolation and must interact with a G protein to elicit a response. It is possible that the G protein with which the receptor interacts selects for a receptor conformation having a unique agonist profile and that the observed affinity and intrinsic efficacy of the agonist-receptor complex may be G protein-specific or influenced by other proteins interacting with the receptor (Leff et al., 1997; Berg et al., 1998) . Second, because it is difficult to measure receptor activation directly, most assays involve measuring a downstream response, and the corresponding EC 50 and E max values may vary, depending on the point in the signaling cascade at which the experimenter measures the response. Therefore, the magnitude of the response elicited by a GPCR is usually not proportional to receptor activation, and EC 50 and E max are not equivalent to observed affinity and intrinsic efficacy. Rather, EC 50 and E max depend on the receptor, proteins interacting with the receptor, and a long list of downstream elements that affect the sensitivity of the response. Because the number of nonreceptor entities that affect observed affinity and intrinsic efficacy is small compared with the long list of cellular components affecting EC 50 and E max , it would seem that observed affinity and intrinsic efficacy would be useful parameters for the characterization of the agonist-GPCR complex across different assays. The estimation of these parameters, however, requires additional data not obtained in high throughput screens. Fortunately, it is possible to estimate the product of observed affinity and intrinsic efficacy of an agonist relative to that of a standard agonist just through analysis of the concentration-response curves (Ehlert et al., 1999; Ehlert and Griffin, 2001 ). This product is equivalent to the potency ratio that an agonist would exhibit relative to a standard agonist in a hypothetical, highly sensitive assay in which both agonists behave as full agonists, even if one or both have very little observed intrinsic efficacy. When viewed from this perspective, estimation of the product of observed affinity and efficacy provides a means of converting potential differences in both the EC 50 and E max values of agonists into a single, relative measurement, analogous to the potency ratio. Therefore, the product of observed affinity and intrinsic efficacy should be a useful, receptor-dependent parameter for measuring agonist activity at GPCRs.
Here we describe methods for analyzing agonist concentration-response curves to estimate the product of observed affinity and intrinsic efficacy expressed relative to that of a standard agonist. We refer to this product as intrinsic relative activity (RA i ). The calculations are the same as those used in the analysis of allosterism in which the control agonist concentration-response curve is compared with one whose properties of affinity and efficacy have been modified allosterically (Ehlert, 1988 (Ehlert, , 2005 . This situation is analogous to comparing the concentration-response curves of two different agonists with differing affinities and efficacies. We have estimated the RA i values of a group of agonists for eliciting responses through the human M 2 receptor coupled to G i , G ␣15 , and G s to determine whether the G protein with which the M 2 receptor interacts influences the activity of the selected agonists. Although most of the agonists investigated exhibited similar RA i values for triggering M 2 muscarinic responses through the different G proteins, compound McN-A-343 exhibited ϳ10-fold greater activity when stimulating M 2 -G ␣15 responses compared with M 2 -G i responses. Our results show that RA i is a useful parameter for the estimation of agonist activity across different assays.
Materials and Methods

Cell Culture
Chinese hamster ovary (CHO) cells stably expressing the human M 2 muscarinic receptor (CHO M 2 cells) were obtained from Acadia Pharmaceuticals (San Diego, CA) and cultured in Dulbecco's modified Eagle's medium with high glucose plus L-glutamine (DMEM) supplemented with 10% fetal calf serum, penicillin-streptomycin (100 units/ml) and G 418 (0.3 mg/ml) at 37°C in a humidified atmosphere with 5% CO 2 . HEK 293T cells stably expressing G ␣15 (HEK G ␣15 ) were kindly provided by Dr. Olivier Civelli (University of California, Irvine, Irvine, CA) and were grown in DMEM containing 10% fetal calf serum, penicillin-streptomycin (100 units/ml), G 418 (0.4 mg/ml), and puromycin (0.625 g/ml). A plasmid containing the human M 2 receptor (hM 2 pCD clone) was kindly provided by Dr. Tom Bonner (National Institutes of Health, Bethesda, MD) and subcloned into a hygro(Ϫ)pcDNA3.1 vector as described previously (Griffin et al., 2003) . HEK G ␣15 cells were transiently transfected with the human M 2 receptor (HEK G ␣15 M 2 cells) using Lipofectamine 2000 and 15 g of the M 2 vector. HEK 293T cells were stably transfected with the human M 2 receptor in the same manner, and clones of stably transfected cells (HEK M 2 ) were isolated in DMEM containing 10% fetal calf serum, penicillin-streptomycin (100 units/ml), hygromycin (0.2 mg/ml), and G 418 (0.4 mg/ml).
cAMP Accumulation
The effects of muscarinic agonists on forskolin-or isoproterenolstimulated cAMP accumulation was measured in CHO M 2 and HEK M 2 cells using a modification of the [ 3 H]adenine prelabeling method of Schultz et al. (1972) and the chromatography procedure of Salomon et al. (1974) . Confluent cell monolayers grown in T75 flasks were washed with DMEM media and then incubated in 9 ml of DMEM containing [ 3 H]adenine (60 Ci) and adenine (3 M) for 1 h at 37°C in 5% CO 2 . Cells were washed twice with DMEM and harvested using trypsin. The resulting cell suspensions were centrifuged for 10 min at 350g, suspended in Krebs-Ringer bicarbonate (KRB) buffer (124 mM NaCl, 5 mM KCl, 1.3 mM MgCl 2 , 26 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 1.8 mM CaCl 2 , and 10 mM glucose) at pH 7.4 and centrifuged a second time. Ultimately, cells were suspended in KRB buffer (12 ml) containing isobutylmethylxanthine (0.5 mM) and incubated for an additional 10 min at 37°C before use in the cAMP assay. Muscarinic agonist-mediated inhibition of cAMP accumulation was carried out in plastic tubes containing intact cells, forskolin (10 M), isobutylmethylxanthine (0.5 mM), and various concentrations of a muscarinic agonist in a final volume of 0.35 ml of KRB buffer. The reaction was started by the addition of an aliquot (300 l) of cells and was stopped by addition of an aliquot (200 l) of ice-cold 30% (w/v) trichloroacetic acid. After at least 30 min on ice, the tubes were centrifuged for 10 min at 3000g, and an aliquot (0.5 ml) from each tube was applied to a Dowex 1.5-ml column (AG-50W-X4, 200 -400 mesh) and washed with two aliquots of water (1.25 ml each) to remove [ 3 H]ATP. The [ 3 H]cAMP was eluted onto a column of neutral alumina (0.6 g) with 4 ml of water and then eluted into scintillation vials with 4 ml of 0.1 M imidazole HCl (pH 7.5). The samples were counted by liquid scintillation spectroscopy. In experiments in which muscarinic agonist-mediated stimulation in cAMP accumulation was measured, cells were first treated overnight (16 -18 h) with pertussis toxin (0.1 g/ml; final concentration) before labeling with [ 3 H]adenine.
Phosphoinositide Hydrolysis
Muscarinic agonist-mediated stimulation of phosphoinositide hydrolysis was measured in suspensions of HEK G ␣15 and HEK G ␣15 M 2 cells using a modification of the [ 3 H]inositol prelabeling method of Berridge et al. (1982) and the extraction method of Kendall and Hill (1990) . Confluent cell monolayers grown in T75 flasks were washed with DMEM and then incubated in 9 ml of DMEM containing [
3 H]inositol (45 Ci) for 16 to 18 h at 37°C in 5% CO 2 . Cells were washed twice with DMEM and harvested using trypsin as described above. Ultimately, the cell pellet was suspended in KRB buffer (15 ml) containing LiCl (10 mM) and incubated at 37°C for 15 min. Muscarinic agonist-mediated stimulation of [ 3 H]-inositol phosphate accumulation was performed in plastic tubes containing intact cells, LiCl (10 mM), and various concentrations of muscarinic agonist in a final volume of 333 l of KRB buffer. The reaction was started with the addition of an aliquot (300 l) of cell suspension, and the mixture was gassed with O 2 -CO 2 , capped with a rubber stopper, and incubated at 37°C for 15 min. The reaction was stopped with 5% perchloric acid (200 l), and the tubes were placed on ice. [ 3 H]Inositol phosphates were isolated as described previously (Tran et al., 2006) .
In some experiments, cells were treated with pertussis toxin (0.1 g/ml final concentration) overnight during the incubation with [ 3 H]inositol. In experiments using 4-DAMP mustard, AF-DX 116 was added to cells after labeling with [ 3 H]inositol to give a final concentration of 4 M. After a 10-min incubation (37°C and 5% CO 2 ), a small volume of 4-DAMP mustard was added (final concentration 40 nM), and the cells were allowed to incubate for 1 h at 37°C and 5% CO 2 . Immediately before use, 0.4 mM 4-DAMP mustard was cyclized to the aziridinium ion by a 30-min incubation at 37°C in 10 mM NaKPO 4 , pH 7.4 . After 4-DAMP mustard treatment, cell monolayers were washed 3 times with DMEM to remove AF-DX 116 and unreacted 4-DAMP mustard and its transformation products.
Preliminary Analysis of Agonist Concentration-Response Curves
The maximal response (E max ), concentration of agonist eliciting a half-maximal response (EC 50 ), and the Hill slope (n) were estimated from the agonist concentration-response curve by nonlinear regression analysis using Prism (GraphPad Software, Inc., San Diego, CA). The data for agonist-mediated inhibition of cAMP accumulation were fitted to the following equation:
in which P denotes cAMP accumulation elicited by forskolin or isoproterenol in the absence of muscarinic agonist and E max denotes the maximal percent inhibition of cAMP accumulation. The agonist concentration-response curve for stimulation of phosphoinositide hydrolysis and enhancement of forskolin-stimulated cAMP accumulation in pertussis toxin treated cells was fitted to the following equation:
In this equation, P denotes the basal value of phosphoinositide hydrolysis measured in the absence of agonist. The dissociation constant of an antagonist (K I ) was estimated on the basis of its ability to antagonize the response to an agonist competitively. The following equation was used to estimate K I :
In this equation, I denotes the concentration of the antagonist used in the assay, and CR denotes the EC 50 value of the agonist measured in the presence of the antagonist divided by that measured in its absence.
Estimation of RA i
To reduce error in the estimation of RA i , we always tested the standard agonist carbachol together with the test agonist in the same experiment. In most instances, all five agonists were tested simultaneously. Our methods for the estimation of RA i represent a further refinement in our previously published methods (Ehlert et al., 1999; Ehlert and Griffin, 2001 ). We define the RA i value of test agonist B relative to standard agonist A as the product of the observed intrinsic efficacy and affinity of agonist B divided by that for agonist A: (Ehlert et al., 1999) :
In this equation, subscripts are used to denote the EC 50 values of A and B. When the E max value of the test agonist is different from that of the standard agonist, the analysis is more complicated, and three different methods have been developed to estimate RA i in this situation, each with its own advantages and disadvantages. These are 1) a null method, which is independent of the relationship between occupancy and response, 2) a method based on the operational model, assuming a logistic relationship between occupancy and response, and 3) a special case of the operational model in which the Hill slope of the agonist concentration-response curve is equivalent to 1. Null Method. The null method involves comparing equiactive concentrations of the test agonist B and the standard agonist A. In our description of the method, we designate the standard agonist as the agonist with the larger E max . An advantage of this method is that it is suitable for the analysis of any shape of concentration-response curve as long as the curve is a continuous, increasing function of the agonist concentration. The method involve three steps: 1) estimation of pairs of equiactive concentrations of agonist A and B, 2) nonlinear regression analysis of these equiactive concentrations according to eq. 8, and 3) calculation of the RA i value using eq. 9, which requires parameter estimates from step 2.
Pairs of equiactive agonist concentrations (A i and B i ) are estimated as follows. The values of B i are simply those of the concentration-response curve of test agonist B, with the subscript i denoting the different concentrations. Each corresponding A i value is estimated from the concentration-response curve of agonist A by interpolating an A i value that yields a response equivalent to that elicited by B i . This interpolation is shown graphically in Fig. 3 . Different methods of interpolation can be used, depending upon the shape of the concentration-response curve of A. In our experiments, the responses to all of the agonists were consistent with eqs. 1 and 2. Consequently, we rearranged these equations to solve for the agonist concentration (X) as a function of the response (R). Thus, eq. 1 was rearranged into the following form to interpolate A i values from the concentration-response curve for inhibition of cAMP accumulation:
In this equation, R i-B denotes the response elicited by the ith concentration of B (B i ), and EC 50-A , E max-A , and n A denote the bestfitting parameter estimates of the concentration-response curve of the standard agonist A. For agonist-stimulated phosphoinositide hydrolysis in HEKG ␣15 cells and agonist-mediated enhancement of forskolin-stimulated cAMP accumulation in pertussis toxin-treated CHO M 2 cells, eq. 2 was rearranged to the following to enable an interpolation of A I values:
Thus, by substituting in the response values of the concentrationresponse curve to B into the corresponding eqs. 6 and 7, it was possible to estimate a set of A i values equiactive to those of B i . The resulting pairs of equiactive agonist concentrations were fitted to the following equation by nonlinear regression analysis:
Agonist-Directed Signaling at the Muscarinic M 2 Receptor
The derivation of this equation is given under Appendix, and it represents the log form of eq. 19. The parameters p and q are defined under Appendix (see eqs. 20 and 21) and are equivalent to the observed affinity and efficacy of B relative to A, respectively. As described under Results, there are an infinite number of parameter estimates that yield the least-squares fit; however, the solution set is unique in that the ratio q/p is constant. Thus, it was possible to estimate q/p by fixing the parameter K A to an arbitrarily high value and determining the values of q and p that minimized the residual sum of squares. Additional details of the regression analysis are given under Results, and a method for obtaining initial parameter estimates for the iterative procedure is given in the last section under Appendix. The RA i value can be calculated as
Substitution of eqs. 20 and 21 for p and q shows that eq. 9 reduces to eq. 4. It is possible to estimate the dissociation constant of the test agonist (K B ) as
in which K A denotes the constant to which K A was fixed during regression analysis. Operational Model. When the agonist concentration-response curve is consistent with a logistic equation (eq. 1 or 2), it is possible to estimate the RA i value of a partial agonist B relative to a more efficacious agonist A by first fitting the concentration-response curves of A and B to the operational model of Black and Leff (1983) by nonlinear regression analysis:
in which R denotes the response to the agonist, X denotes the concentration of A or B, and is defined in eq. 25 under Appendix.
For the experiments involving agonist stimulation of phosphoinositide hydrolysis and stimulation of cAMP accumulation in CHO M 2 cells treated with pertussis toxin, the response denotes the measurement minus the basal value observed in the absence of agonist. For the experiments involving agonist-mediated inhibition of forskolinor isoproterenol-stimulated cAMP accumulation, the response represents the percentage inhibition of cAMP accumulation. 
By making the appropriate substitutions for (eq. 25 under Appendix), it can be shown that eq. 12 reduces to eq. 4.
Hill Slope Equals 1. When the Hill slope of the agonist concentration-response curve is equal to 1, the RA i value of agonist B relative to standard agonist A is calculated as
If the definition of (eq. 25) is substituted into eqs. 27 and 28, and these latter equations are then substituted for the E max and EC 50 values into eq. 13, then it can be shown that eq. 13 reduces to eq. 4.
Drug and Chemicals
Drugs and chemicals were obtained from the following sources: . 4-DAMP mustard was synthesized as described previously . The enantiomers of aceclidine were synthesized and resolved as described by Ringdahl et al. (1979) .
Results
Phosphoinositide Hydrolysis. We investigated the ability of muscarinic agonists to elicit phosphoinositide hydrolysis through the M 2 muscarinic receptor in HEK G ␣15 cells. The highly efficacious muscarinic agonist, oxotremorine-M, elicited a small phosphoinositide response in HEK G ␣15 cells, presumably through activation of an endogenous muscarinic receptor. When the latter cells were transiently transfected with the human M 2 muscarinic receptor, the resulting cells (HEK G ␣15 M 2 ) exhibited a robust phosphoinositide response to oxotremorine-M (Fig. 1a) . The response was resistant to treatment with pertussis toxin (0.1 g/ml, overnight incubation; data not shown). To identify the endogenous receptor mediating phosphoinositide hydrolysis in HEK G ␣15 cells, we characterized the antagonism of the response by subtypeselective muscarinic antagonists. When measured in the presence of either AF-DX 116 (10 M) or pirenzepine (1.58 M), the concentration-response curve to oxotremorine-M shifted to the right 17-and 14-fold, respectively. These antagonist-induced shifts correspond to calculated pK I values of 6.20 Ϯ 0.095 and 6.89 Ϯ 0.19 for AF-DX 116 and pirenzepine, respectively (see eq. 3). Collectively, these pK I values agree with the corresponding binding affinities (pK D values) of AF-DX 116 and pirenzepine at the human M 3 muscarinic receptor (6.10 Ϯ 0.06 and 6.59 Ϯ 0.03) but not those of the M 1 (6.24 Ϯ 0.03 and 7.77 Ϯ 0.03), M 2 (7.27 Ϯ 0.05 and 5.96 Ϯ 0.05), M 4 (6.96 Ϯ 0.12 and 7.23 Ϯ 0.02), or M 5 muscarinic receptor (5.29 Ϯ 0.11 and 6.55 Ϯ 0.06). Consequently, we conclude that the M 3 subtype mediates phosphoinositide hydrolysis in HEK G ␣15 cells.
To eliminate this M 3 response, we treated cells with the irreversible muscarinic antagonist 4-DAMP mustard in combination with the competitive M 2 selective antagonist AF-DX 116 for 60 min followed by washing. This treatment has been shown to cause 93% inactivation of M 3 receptors while only inactivating M 2 by 22% (Griffin et al., 2003) . As shown in Fig.  1b , 4-DAMP mustard treatment completely eliminated the response to the endogenous M 3 receptor in HEK G ␣15 cells while having little inhibitory effect on that measured in HEK G ␣15 M 2 cells.
Having developed a simple method for investigating the signaling of the M 2 receptor through G ␣15 , we measured the ability of a group of agonists with varying potencies and intrinsic efficacies to stimulate phosphoinositide hydrolysis in HEK G ␣15 M 2 cells, which had been previously treated with 4-DAMP mustard. We also treated these cells with pertussis toxin (0.1 g/ml) overnight to prevent M 2 receptor signaling through G i/o . Figure 2a shows the results of these experiments. Oxotremorine-M, carbachol, and S-aceclidine all elicited potent responses with similar E max values, whereas R-aceclidine and McN-A-343 behaved as partial agonists. Table 1 lists the EC 50 , E max , and Hill slope values for these experiments. We also investigated the ability of the same group of agonists to stimulate phosphoinositide hydrolysis in HEK G ␣15 cells that had not been transfected with the M 2 receptor nor treated with 4-DAMP mustard (Fig. 2b) . Under these conditions, the agonists were less potent and R-aceclidine and McN-A-343 produced barely detectable responses. Table 2 summarizes the results of these experiments. Estimation of Agonist RA i Values for Phosphoinositide Hydrolysis in HEK Cells. We estimated the RA i values of agonists from the data shown in Fig. 2a using the procedures described under Materials and Methods. Figure 3 illustrates our use of the null method to estimate the RA i value of McN-A-343 relative to carbachol. First, predicted concentrations of carbachol that elicit responses equivalent to those of the concentration-response curve to McN-A-343 were interpolated as shown in Fig. 3a using eq. 7. These interpolated concentrations are plotted against the corresponding equiactive concentrations of McN-A-343 in Fig. 3b . Equation 8 was fitted to the data by nonlinear regression analysis to estimate p, q, and K A ; however, an infinite number of parameter values yield the same least-squares fit. Consequently, it is impossible to find a solution set consisting of single values of these parameters. When the value of K A was fixed as a constant; however, it was possible to obtain a least-squares fit corresponding to unique values of p and q and the constant K A . As the value of log K A was set at various values between Ϫ7.5 and an arbitrarily high value of Ϫ1, the best-fitting values of p and q decreased proportionately so that their ratio remained constant as well as the residual sum of squares (RSS). Thus, it was possible to estimate the ratio p/q even though it was impossible to estimate unique values of K A , p, and q. The RA i of McN-A-343, expressed relative to carbachol is simply calculated as the ratio q/p (see eq. 9). The RA i values of S-and R-aceclidine were estimated using a similar strategy. Because the E max value of carbachol was less than those of oxotremorine-M and S-aceclidine, we first calculated the RA i values of carbachol and S-aceclidine relative to oxotremorine-M and then expressed the resulting RA i values relative to carbachol. A summary of these estimates is given in Table 1 . We estimated the dissociation constants of the partial agonists R-aceclidine (pK ϭ 3.81 Ϯ 0.37) and McN-A343 (pK ϭ 4.63 Ϯ 0.15) using eq. 10.
We also used the operational model to estimate the RA i values of the agonists. First, we fitted the concentrationresponse curves shown in Fig. 2a to eq. 11 using global nonlinear regression analysis, sharing the estimates of M sys and m among the curves and estimating unique values of and K for each curve. It was possible to obtain unique estimates of all of the parameters using this method; however, the estimates of and K for the full agonists were poorly defined and exhibited huge standard errors as well as the estimate of M sys . This limitation arises with full agonists or, in other words, whenever the E max value is approximately equal to the maximum response of the system (M sys ). Nevertheless, the ratio of /K for each agonist was well defined. Thus, it was possible to estimate the RA i value of each agonist by taking the ratio of the /K of each agonist relative to that of carbachol as shown by eq. 12. The RA i estimate of each agonist is listed in Table 1 together with the values estimated by the null method. It can be seen that there is close agreement between the two methods. It was also possible to estimate the dissociation constants of the partial agonists, R-aceclidine (pK ϭ 3.64 Ϯ 0.46) and McN-A-343 (pK ϭ 4.93 Ϯ 0.12).
To illustrate the unique relationship among parameter estimates in the operational model, we fixed the log K A value of the standard agonist carbachol (K carb ) at various values between Ϫ6 and Ϫ1 and used nonlinear regression analysis to estimate the best-fitting values of the other parameters. Figure 4b shows the results of this regression analysis for the estimation of the RA i value of McN-A-343 relative to carbachol. It can be seen that once the log K carb value is ϳՆ-5, the RSS drops to a minimum and remains at this low value no matter how large the increase in K carb . Over this range of K carb values, the estimates of m, M sys , McN , and K McN are constant. As log K carb increases from Ϫ5 to Ϫ1, there is a proportional increase in carb such that the ratio of carb /K carb is constant (Fig. 4c) . Figure 4c illustrates that the ratio of McN /K McN is also constant over the domain log K carb ϾϪ5 as well as the estimate of RA i . In summary, the results in Fig. 4 illustrate that it is possible to estimate the RA i value of a partial agonist relative to a full agonist by setting the K A value of the full agonist to an arbitrarily high value and using nonlinear regression analysis to estimate the other parameters in the operational model (eq. 11). The RA i value can then be calculated from these parameters using eq. 12. This analysis for the agonists in Fig. 2 also yielded estimates of m (0.721 Ϯ 0.044), M sys (104 Ϯ 4.7), and the dissociation constants of the partial agonists as listed in the previous paragraph. Figure 4a shows the best fit of the operational model to the concentration-response curves of carbachol and McN-A-343 using this method.
We also estimated the RA i values of the agonists for stimulation of phosphoinositide hydrolysis in HEK G ␣15 M 2 cells using the simple calculation given in eq. 13, which is valid provided that the Hill slopes are similar to 1. The calculation is also reasonably accurate if the Hill slopes differ from 1, and the E max values of the agonists are not less than 50% that of a full agonist. Table 1 lists these estimates. It can be seen that there is close agreement between the estimates using eq. 13 and those estimated with the null method and operational model for all of the agonists exhibiting similar E max values (i.e., oxotremorine-M, carbachol, S-aceclidine, and R-aceclidine). However, the simple estimate of the RA i for McN-A-343 is ϳ3-fold greater than those estimated using the other two methods, which illustrates the flaw in using the simple method when the Hill slopes differ from 1 and there is a large difference in E max between the standard and test agonist.
We also estimated the RA i values of carbachol, oxotremorine-M, S-aceclidine, R-aceclidine, and McN-A-343 for their effects on phosphoinositide hydrolysis in HEK G ␣15 cells that had not been transfected with the M 2 receptor, and these results are summarized in Table 2 .
Agonist-Mediated Inhibition of cAMP Accumulation in CHO M 2 Cells. To determine whether the RA i values of agonist varied depending upon the G protein with which the M 2 receptor interacts, we measured agonist-mediated inhibition of forskolin-stimulated cAMP accumulation in CHO cells stably transfected with the human M 2 muscarinic receptor (Fig. 5a) . Carbachol, oxotremorine-M, and the enantiomers of aceclidine behaved as full agonists and caused a maximal inhibition of cAMP accumulation of ϳ73%, whereas that of McN-A-343 was only 32%. There was a tendency for the maximal effect of R-aceclidine to exceed that of the other full agonists. As described below, R-aceclidine exhibited a nonspecific inhibition of cAMP accumulation at high concentrations (i.e., 1.0 mM). Consequently, we shared the estimate of the E max among the full agonists to prevent an overestimation in the E max of R-aceclidine. The E max , EC 50 , and Hill slope values of these data are summarized in Table 3 . The RA i values of the full agonists were calculated according to eq. 13 and are also listed in Table 3 . Note that when the standard agonist and the test agonist exhibit the same E max , eqs. 5 and 13 yield the same result. The RA i value of McN- A-343 was estimated using eq. 13 as well as the null method and operational model, and these estimates are also shown in Table 3 . In this instance, eq. 13 gave results similar to those for the other two methods, probably because the Hill slopes of carbachol and McN-A-343 were close to 1. The estimates of the negative logarithm of the dissociation constant of McN-A343 using the null method (pK ϭ 4.16 Ϯ 0.24) and the operational model (pK ϭ 4.07 Ϯ 0.16) were approximately the same.
Comparison of the data in Tables 1 and 3 shows that whereas the RA i values of oxotremorine-M, carbachol, Saceclidine, and R-aceclidine are similar, the value for McN-A-343 is ϳ10-fold greater in HEK G ␣15 M 2 cells relative to that measured in CHO M 2 cells. This increase in the RA i value of McN-A-343 was associated with an average 4.5-fold increase in observed affinity (decrease in dissociation constant), indicating a small increase in observed intrinsic efficacy (ϳ2-fold) as well. To verify that this difference can be attributed to different G proteins and not to the cells in which the M 2 receptor was expressed, we investigated M 2 receptormediated inhibition of isoproterenol-stimulated cAMP accumulation in HEK T cells stably expressing the human M 2 muscarinic receptor (HEK T M 2 ). Figure 5b shows the results of these experiments using carbachol and McN-A-343 as agonists. The results of these experiments are summarized in Table 4 where it can be seen that the RA i value of McN-A-343 is similar to that measured in CHO M 2 cells but only ϳ 1 ⁄10 that measured in HEK G ␣15 M 2 cells. These results suggest that McN-A-343 preferentially directs signaling of the M 2 receptor through G ␣15 relative to G i .
Agonist-Mediated Enhancement of Forskolin-Stimulated cAMP Accumulation. Michal et al. (2001) have shown that the M 2 receptor has biphasic effects on cAMP accumulation in CHO cells when forskolin is present. At low concentrations, muscarinic agonists cause a potent inhibition of cAMP accumulation, whereas at high concentrations, an enhancement of cAMP accumulation occurs. The inhibitory effect is mediated via G i and is prevented by pertussis toxin treatment, whereas the stimulatory effect is mediated by G s (Michal et al., 2001 (Michal et al., , 2007 . After pertussis toxin treatment, only the less potent stimulatory phase is observed. Consequently we measured agonist concentration-response curves for stimulating cAMP accumulation in the presence of forskolin (10 M) in CHO M 2 cells that had been previously treated with pertussis toxin to prevent G i -mediated inhibition of adenylyl cyclase (Fig. 6a) . Carbachol, oxotremorine-M, and S-aceclidine all exhibited a similar shaped sigmoid concentration-response curves with similar E max values, whereas R-aceclidine exhibited a bell-shaped curve with a lower maximum. McN-A-343 actually caused a concentration-dependent inhibition of cAMP accumulation. Because both McN-A-343 and R-aceclidine inhibited cAMP accumulation at high concentrations, we measured their effects on forskolin-stimulated cAMP accumulation in CHO cells that had not been transfected with the M 2 muscarinic receptor (Fig. 6b) . Both agonists caused a concentration-dependent inhibition of forskolin-stimulated cAMP accumulation in untransfected CHO cells, suggesting that the compounds interfere with adenylyl cyclase through a nonmuscarinic receptor mechanism at high concentrations. In contrast, carbachol had no such effect. Thus, in analyzing the concentrationresponse curve to R-aceclidine, we only used the data over the log molar concentration range of Ϫ5 to Ϫ3.5 R-aceclidine. The estimates of the RA i values of carbachol, oxotremorine-M, S-aceclidine, and R-aceclidine for stimulation of cAMP accumulation were calculated using the three different methods, and these estimates are listed in Table 4 . There is agreement among the three different estimates for a given agonist. Also the RA i values estimated for stimulation of cAMP accumulation agree generally with those estimated in the other assays. Analysis of the Loss of Activity of McN-A-343 in Stimulating cAMP Accumulation. The lack of effect of McN-A-343 in enhancing forskolin-stimulated cAMP accumulation in CHO M 2 cells treated with pertussis toxin may indicate that the RA i value of McN-A-343 in this assay is less than that observed in the two other assays. Alternatively, it may be that this response is so insensitive that the relatively weak activity of McN-A-343 at the M 2 receptor simply does not register in this assay even though its RA i value may be similar to those observed in the other assays. To discriminate between these two possibilities we determined the loss in sensitivity to carbachol that occurs when stimulation of cAMP accumulation (CHO M 2 G s assay) is measured instead of inhibition of cAMP accumulation (CHO M 2 G i assay), and determined whether an equivalent loss in sensitivity could eliminate the response to McN-A-343 in the CHO M 2 G s assay, assuming no change in its RA i value. Figure 7a shows that the concentration-response curve of carbachol in the CHO M 2 G s assay is shifted to the right 26-fold compared with that for the CHO M 2 G i assay. From the perspective of the operational model, this loss in sensitivity can be attributed to a reduction in to a value only 3.9% of that measured in the CHO M 2 G i assay. If we apply the same loss in sensitivity to the concentration-response curve of McN-A-343 in the CHO M 2 G i assay, the resulting curve only reaches an E max of 1.7% as shown in Fig. 8a by the theoretical curve for McN-A-343 in the CHO M 2 G s assay. This level of stimulation would have been impossible to detect, given the nonspecific inhibitory effect of McN-A-343 on cAMP accumulation. The apparent reduction in the value of carbachol between the two assays can be estimated in the same manner that one estimates RA i , except that in this instance, we are estimating the activity of carbachol in the CHO M 2 G s assay relative to its activity in the CHO M 2 G i assay. Because carbachol behaves as a full agonist in both assays, its value in the CHO M 2 G s assay relative to that of the CHO M 2 G i assay is simply equivalent to the ratio of its EC 50 value in the G i assay expressed relative to that for the G s assay. We also carried out a similar type of analysis for the loss in sensitivity to carbachol in the CHO M 2 G s assay compared with the HEK G ␣15 M 2 assay (Fig. 8b) . In the latter case, the loss in sensitivity to carbachol corresponded to a reduction in of 77%, and this change nearly, but not completely, eliminated the theoretical response to McN-A343 in the CHO M 2 G s assay, assuming no change in RA i between the two assays. The E max of the theoretical response was 7%, and this level of stimulation would have been difficult to detect given the small nonspecific inhibitory effects of McN-A-343 over the same concentration range. Thus, we conclude that the decreased sensitivity of the CHO M 2 G s assay can account for the loss in the response to McN-A-343, and it is impossible to tell from the data whether the actual RA i value of McN-A-343 in the CHO M 2 G s assay is any less than those observed in the HEK G ␣15 M 2 and CHO M 2 G i assays.
Discussion
We have described a method for estimating the product of observed affinity and intrinsic efficacy of an agonist for a receptor expressed relative to that of another using only a single concentration-response curve for each agonist. This measure (RA i ) provides a means of converting EC 50 and E max values into a single estimate, enabling one to compare the activity of an agonist across different assays, regardless of whether the agonist behaves as a full or partial agonist. Our results show that carbachol, oxotremorine-M, and the enantiomers of aceclidine have similar activity across the different M 2 assays, whereas McN-A-343 exhibits ϳ10-fold greater activity at the M 2 receptor signaling through G ␣15 compared with G i (Fig. 8a) . This ability of McN-A-343 to select for M 2 -G ␣15 responses is important in drug screening because G ␣15 is often used to transduce signals through GPCRs.
If an agonist induces or selects a receptor conformation that preferentially interacts with G 15 , then the agonist should exhibit a larger RA i value for eliciting G 15 responses relative to a standard agonist that lacks this selectivity. Presumably, this phenomenon explains the selectivity of McN-A-343 for G 15 responses relative to G i responses. This selectivity for G 15 responses should be manifest when the agonist is assayed in different cells, each expressing a single G protein (e.g., G 15 or G i ). If both G proteins are expressed within the same cell and the receptor is in a dynamic equi- jpet.aspetjournals.org librium with both, then the RA i value of an agonist for responses mediated through either G protein should be the same and equal to a weighted average of those observed in different cells (Leff et al., 1997) . Bearing this hypothesis in mind, we treated HEK G ␣15 M 2 cells with pertussis toxin to prevent M 2 receptor signaling through G i when G ␣15 responses in HEK G ␣15 M 2 cells were measured so that our RA i estimate would reflect only the M 2 -G ␣15 interaction. Nevertheless we also performed the same experiments without pertussis toxin treatment and observed essentially the same results for McN-A-343 and the other agonists (data not shown). Perhaps the selectivity of the McN-A-343-M 2 receptor complex for G 15 is so great that G i does not compete effectively and causes little perturbation of the M 2 receptor-G 15 interaction. Alternatively, these findings may suggest that different pools of M 2 receptors are dedicated to either G 15 or G i and that the M 2 receptor is not in equilibrium with both G proteins at the same time in HEK G ␣15 M 2 cells. We speculate that this compartmentalization might be maintained by scaffolding or accessory proteins as established for other systems (Ostrom et al., 2000) .
It is possible that the M 2 receptor-mediated enhancement in forskolin-stimulated cAMP accumulation has little physiological relevance. We found that muscarinic agonists cause little or no increase in cAMP accumulation in pertussis toxintreated CHO cells unless forskolin is present. Presumably, forskolin enhances the weak activation of G s by muscarinic agonists in CHO cells so that a substantial activation of adenylyl cyclase can be measured in cells treated with pertussis toxin. It has been shown that type VI adenylyl cyclase is abundantly expressed in CHO cells (Varga et al., 1998) and that this isozyme exhibits synergistic interactions between forskolin and G s (Sutkowski et al., 1994) . Thus, although the M 2 receptor-G s interaction may be too weak to subserve a physiological role, it nonetheless provides an interesting opportunity to test whether the nature of the G protein with which the receptor interacts influences agonist activity.
The RA i values that we reported for muscarinic agonists in the CHO M 2 G i assay are consistent with the activity of these agonists reported in the electrically driven guinea pig left atrium (Fig. 8b) . This preparation is a standard assay for the M 2 muscarinic receptor signaling through a G i mechanism. We estimated the RA i values of the agonists in this preparation from published reports of the EC 50 and E max values (Eltze et al., 1993; Barocelli et al., 2000) using eq. 13 and also using regression analysis (eq. 11) of the concentration-response curves for carbachol and McN-A-343 published by Christopolous and Mitchelson, 1997) . The good agreement between the two sets of data illustrate the usefulness of the RA i estimate in predicting agonist activity at the same receptor-G protein signaling mechanisms across different assays.
One way to appreciate the significance of RA i is to consider a series of agonists in a hypothetical, highly sensitive assay in which the agonists would behave as full agonists, even those with little intrinsic efficacy. In this situation, the RA i values would be equivalent to the ratio of EC 50 values of the agonists expressed relative to a standard agonist. To illustrate this point, we show a comparison of the RA i values of muscarinic agonists for stimulating contractions in the guinea pig ileum with those for stimulating phosphoinositide hydrolysis in CHO cells transfected with the human M 3 Tables 1, 3 , and 5 and represent the mean values calculated using the null method and the operational model, except for the values of the full agonists in Table 3 , which were calculated using eq. 13. b, the RA i values of muscarinic agonists for inhibiting cAMP accumulation in CHO M 2 cells and for inhibiting the electrically driven guinea pig left atrium are shown. The values for carbachol, the enantiomers of aceclidine and McN-A-343 were calculated using eq. 13 and the EC 50 and E max values published by Eltze et al. (1993) for the isolated atrium. Another estimate for McN-A-343 in the atrium was calculated from the data of Christopolous and Mitchelson (1997) by regression analysis using eq. 11, and this estimate was averaged with that from Eltze et al. (1993) . The RA i value for oxotremorine-M was estimated from the data of Barocelli et al. (2000) and was first calculated relative to oxotremorine using eq. 13 and then expressed relative to carbachol using the data of Eltze et al. (1993) . c, the RA i values of muscarinic agonists for eliciting phosphoinositide hydrolysis in CHO M 3 cells and contraction of the guinea pig ileum are shown. The latter data are from Ehlert et al. (1999) . receptor (Fig. 8c) . In the former assay, most of the agonists behave as full agonists, whereas in the latter, most behaved as partial agonists (Ehlert et al., 1999) . There is exceptional agreement in the RA i values of agonists across these two M 3 receptor-G q responses.
An interesting property of RA i is related to the initial slope of the agonist concentration-response curve. By taking the first derivative (dy/dX) of the operational model (eq. 11) with respect to the agonist concentration (X) and evaluating its limit as the agonist concentration approaches 0, it is possible to estimate the initial slope of an agonist concentrationresponse curve. If the initial slope for agonist B is divided by that of a standard agonist A, the result is RA i m , where which m denotes the transducer slope factor in the operational model:
In these equations, X denotes the concentration of agonist with subscripts for test agonist (B) and standard agonist (A). Thus, when considered from this perspective, the RA i m is a relative measure of the sensitivity of receptor-G protein complexes for different agonists. The initial slope of the plot of output against signal intensity is a common means of expressing the sensitivity of a transducer in electronics and engineering.
GPCRs are unique in that observed affinity is influenced by the concentration of guanine nucleotide in the cytosol, particularly for G i and G s linked receptors. As the concentration of GTP and GDP increases, observed affinity decreases. This change in affinity occurs with a corresponding opposite change in intrinsic efficacy such that the product of observed affinity and intrinsic efficacy remains constant (Ehlert and Rathbun, 1990; Ehlert, 2000) . Consequently the RA i estimate is unperturbed by changes in the guanine nucleotide concentration, making it an ideal measurement of activity in cells with different concentrations of GTP or in broken cell assays in which the guanine nucleotide concentration is manipulated [e.g., agonist stimulated guanosine 5Ј-O- (3-[ 35 S]thio)triphosphate binding].
Although the regression methods that we used for estimating RA i values using the null method (eq. 8) and the operational model (eq. 11) may seem complicated, a computer algorithm can be written to make these calculations automatic, like the estimation of EC 50 and E max . We think that the RA i estimate has widespread application in comparing agonist activity across different assay systems and in detecting agonist-directed signaling. Analogous types of calculations can be used to analyze allosterism (Ehlert, 2005) , sitedirected mutagenesis (Ehlert, 2000) and the loss of function in knockout mice when more than one receptor contributes to the function (Tran et al., 2006) .
APPENDIX
Theoretical Basis for the Estimation of RA i . This section describes the theoretical basis for the equations used to estimate the RA i values of agonists. Our method for the estimation of RA i is based on a further development of our previous methods (Ehlert et al., 1999; Ehlert and Griffin, 2001 ). In our analysis we assume that the amount of receptor activation to agonist X is proportional to the stimulus as defined by Furchgott (1966) :
in which X denotes the intrinsic efficacy of X, R T denotes the concentration of functional receptors, and K X denotes the equilibrium constant. The response to agonist X can be represented as a function (f) of the stimulus:
Below, three different approaches for estimating the RA i value of an agonist relative to a standard agonist are described. The first involves eliminating the stimulus-response function from the analysis through the use of a null method. The second involves the use of the operational model to describe the stimulus-response function, and the third involves a special case of the operational model in which the Hill slope of the concentration-response curve equals 1. Null Method. One approach to estimation of RA i is to compare equivalent tissue responses to the two agonists so that the unknown relationship between the stimulus and response (f) is eliminated. By using this approach, the relationship describing equivalent tissue responses to agonist B and standard agonist A is given by 
As described under Materials and Methods (eq. 13), the RA i value can be estimated from the ratio q/p. Operational Model. Although the null method just described has the advantage of being applicable for any type of stimulus-response function (i.e., any shape of concentrationresponse curve), it is widely observed that agonists usually exhibit logistic concentration-response curves. Indeed, a curve-fitting procedure based on the following logistic equation is the most common computational method that investigators use to estimate the E max and EC 50 :
in which n denotes the Hill slope. Several investigators have shown that if the input to the stimulus-response function (f) is the stimulus (i.e., product of receptor occupancy and intrinsic efficacy) and the output obeys the logistic function just described, then the stimulus-response function must be the following (Furchgott, 1966; Mackay, 1981; Kenakin and Beek, 1982; Black and Leff, 1983) :
in which M sys denotes the maximum response of the system, K E denotes the sensitivity of the stimulus-response function, and m denotes the transducer slope factor. This exponent is related to, but not identical to, the Hill slope of the agonist concentration-response curve. Substitution of eq. 16 for S in eq. 23 above followed by simplification yields
in which
As described under Materials and Methods, the RA i value of an agonist can be estimated from the K X and X values of the agonist (see eq. 12). In situations in which the transducer slope factor m in eq. 24 equals 1, the Hill slope of eq. 22 is also equal to 1 (n ϭ 1), and eq. 24 reduces to response ϭ XE max X ϩ EC 50 (26) (Microsoft Office, 2004 ) to obtain the least-squares fit to eqs. 8 and 11 when RA i was estimated by the null method and operational model, respectively. The approach is analogous to that described by Christopoulos and Mitchelson (1998) , but the regression equations are changed appropriately for our analysis. This regression analysis requires initial parameter estimates, and below we describe a means to calculate these when analyzing a partial agonist (B) with a standard full agonist (A). For the null method, the value of K A is fixed to an arbitrarily high value (e.g., log molar K A ϭ Ϫ1) and the initial estimates of p and q (pЈ and qЈ, respectively) are estimated as follows: 
In eq. 31, K A denotes the arbitrarily high value to which K A is set as a constant for the regression analysis.
